Varun Chawla

Dr. Varun Chawla is a board-certified nephrologist with over twelve years of clinical practice and leadership experience in community-based kidney care, clinical research, and medical education. He holds an MBBS from the All India Institute of Medical Sciences in New Delhi, completed his Internal Medicine residency at Mount Auburn Hospital affiliated with Harvard Medical School, and pursued his Nephrology Fellowship at Beth Israel Deaconess Medical Center, also affiliated with Harvard Medical School. Dr. Chawla further distinguished his academic credentials by earning a Master of Public Health with a focus on Epidemiology and International Health from the Harvard School of Public Health. He maintains active board certification through the American Board of Internal Medicine in both Internal Medicine and Nephrology, with recent recertifications in 2021 and 2022 respectively, and holds an active California medical license.

Since 2012, Dr. Chawla has served as a Partner at West Coast Kidney Institute in Fremont, California, and maintains staff privileges at Washington Hospital and St. Rose Hospital. His clinical expertise encompasses chronic kidney disease, diabetic kidney disease, resistant hypertension, hyperkalemia management, dialysis therapies, renal bone disease, and glomerular diseases including IgA nephropathy. As Principal Investigator, he currently leads multiple Phase 3 clinical trials including BaxDuo-ARCTIC, BaxDuo-PACIFIC, and RAINIER, involving thousands of participants across global sites and addressing critical nephrology therapeutic areas.

Dr. Chawla has published extensively in peer-reviewed journals including the Clinical Journal of the American Society of Nephrology, Journal of the American Society of Nephrology, and Clinical Transplantation, with research focusing on diabetic nephropathy, dialysis access disparities, and chronic kidney disease outcomes. He has also contributed a textbook chapter on Alport Syndrome and serves as a frequent speaker at continuing medical education programs. Since 2019, he has provided advisory and consulting services to multiple biopharmaceutical companies, offering expertise in protocol development, clinical trial design, and translating evidence into clinical practice.